Palliative care in 9 children with neurodegeneration with brain iron accumulation

Tomasz Dangel1, Tomasz Kmieć2, Artur Januszaniec3

  • 1Warsaw Hospice for Children Foundation, Agatowa 10, 03-680, Warsaw, Poland. dangel@hospicjum.waw.pl.

Insights

Pediatric palliative home care effectively managed neurodegeneration with brain iron accumulation (NBIA) symptoms, improving quality of life for children and families. Botulinum toxin and ketogenic diets were key interventions.

Area of Science:

  • Pediatric Neurology
  • Palliative Care
  • Rare Diseases

Background:

  • Neurodegeneration with Brain Iron Accumulation (NBIA) presents significant challenges for affected children and their families.
  • Effective management strategies for NBIA are crucial to improve patient quality of life and provide family support.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of pediatric palliative home care for children with NBIA.
  • To assess the impact of multidisciplinary interventions, including botulinum toxin injections and dietary management, on patient well-being.
  • To gauge parental satisfaction with the provided palliative home care services.

Main Methods:

  • A multidisciplinary team provided home-based palliative care to 9 NBIA patients.
  • Skeletal health was assessed using densitometry.
  • Botulinum toxin was administered for spasticity and dystonia management.
  • Parental satisfaction was evaluated via a custom questionnaire.

Main Results:

  • Palliative home care averaged 1569 days, with a median patient age of 9 years at admission.
  • Botulinum toxin injections reduced spasticity, pain, and deformities, while a ketogenic diet increased body mass in most patients.
  • Despite reduced bone density, palliative care was positively evaluated by parents.
  • Median age at death was 11 years for 6 patients.

Conclusions:

  • Palliative home care represents an optimal treatment approach for children diagnosed with NBIA.
  • Multidisciplinary interventions can significantly alleviate symptoms and improve the quality of life for NBIA patients.
  • Home-based care facilitates comprehensive management and support for children with rare neurodegenerative conditions.
Abstract

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
718
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
905
Continuing Care01:25

Continuing Care

Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.8K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K